The myeloma patient community has no time for business as usual.
Multiple myeloma is a highly heterogenous bone marrow cancer that requires a multitude of drugs to effectively treat every patient. About 30,000 Americans are diagnosed each year, and over 10,000 will die of the disease annually. However, over the last two decades, we’ve made advances in science and technology that were unimaginable a few short years ago, finally putting the cure within reach. As leaders in the industry, the time to use our means, savvy, and foresight to drive the innovation needed us to win the fight against cancer once and for all is now.